The No Surprises Act, a landmark piece of federal legislation designed to protect patients from the financial devastation of unexpected medical bills, is currently facing a critical inflection point as industry stakeholders warn of systemic failures within its primary enforcement mechanism. While the law has been largely successful in its core mission of shielding consumers from "surprise" out-of-network charges, the Independent Dispute Resolution (IDR) process—the administrative framework intended to settle payment disagreements between insurers and providers—has become a source of significant operational and financial strain. During the recent AHIP Medicare, Medicaid, Duals & Commercial Markets Forum, prominent healthcare policy experts and insurance executives voiced urgent concerns that the IDR process is being overwhelmed by a volume of claims far exceeding original government projections, leading to inflated awards and rising premiums for the broader public.
Katy Spangler, a key figure in the Coalition Against Surprise Medical Billing and an early proponent of the 2020 legislation, took the stage at the forum to advocate for immediate structural changes. Her position represents a notable shift; having helped push for the law’s passage, she now finds herself calling for its refinement to prevent what she describes as an unsustainable "abuse" of the system. The tension lies in the gap between the law’s intent—to serve as a final, rarely-used safety net—and its current reality as a high-volume, high-stakes arbitration machine.
The Mechanics of the No Surprises Act and the IDR Framework
To understand the current crisis, it is essential to examine the architecture of the No Surprises Act (NSA). Passed in December 2020 and effective as of January 2022, the law prohibits healthcare providers from billing patients more than the in-network cost-sharing amount for emergency services, certain non-emergency services at in-network facilities, and air ambulance services. Before this law, patients were often caught in the middle of "balance billing," where a provider would bill the patient for the difference between the total charge and what the insurer paid.
Under the NSA, the patient is removed from the financial dispute. Instead, the insurer and the provider are required to enter a 30-day "open negotiation" period to determine a fair payment rate. If an agreement cannot be reached during this window, either party can initiate the IDR process. This process utilizes "baseball-style" arbitration, where both the insurer and the provider submit a final offer. A neutral, third-party arbitrator, known as an IDR entity, must then select one of the two offers. The arbitrator is instructed to consider various factors, including the Qualifying Payment Amount (QPA)—which is the insurer’s median in-network rate for a similar service in that geographic area—as well as the provider’s experience and the complexity of the case.
A Chronology of Implementation and Unforeseen Challenges
The implementation of the IDR process has been marked by administrative hurdles and legal volatility since its inception:
- December 2020: The No Surprises Act is signed into law with bipartisan support.
- January 2022: The law officially takes effect. Almost immediately, the Department of Health and Human Services (HHS) and other agencies face a barrage of lawsuits from provider groups, particularly the Texas Medical Association, challenging the weight given to the QPA in the arbitration process.
- 2022–2023: Federal courts issue several rulings that force the government to revise its guidance for arbitrators, leading to multiple pauses and restarts of the IDR portal. This creates a massive backlog of claims.
- 2024: Data begins to emerge showing that the volume of disputes has eclipsed all initial federal estimates.
- 2025 (Present): Industry leaders at the AHIP forum report that the system is under extreme duress, with billions of dollars in administrative costs and evidence of "gaming" by certain high-volume providers.
Analyzing the Data: Projections vs. Reality
The discrepancy between the government’s expectations and the actual utilization of the IDR process is stark. Kennah Watts, a research fellow at the Center on Health Insurance Reforms (CHIR) at Georgetown University’s McCourt School of Public Policy, presented data at the forum that highlights the scale of the issue. According to the Centers for Medicare & Medicaid Services (CMS), the government originally anticipated approximately 55,000 IDR disputes would be filed between 2022 and mid-2025.
However, the actual figure is staggering: approximately 3.4 million IDR disputes were initiated from 2022 through June 2025. This represents a volume more than 60 times higher than the initial forecast. Furthermore, the data reveals a heavy tilt in who is driving this volume. Watts noted that providers and healthcare facilities are responsible for initiating 99% of all disputes.
The outcomes of these disputes are equally lopsided. Not only are providers filing the vast majority of cases, but they are also winning at significantly higher rates than insurance plans. More concerning to payers and policy advocates is the "win rate" relative to standard market prices. Watts reported that when providers win, the median award is approximately 4.5 times the established in-network rate. This "IDR premium" incentivizes providers to bypass negotiations and head straight for arbitration, hoping for a windfall that far exceeds what they would earn through traditional contract negotiations.
The Operational and Financial Burden on Payers
For insurance carriers, the sheer volume of claims has necessitated a massive expansion of administrative infrastructure. Josh Goldberg, executive director of health policy at Health Care Service Corporation (HCSC), detailed the operational nightmare of managing the IDR influx. HCSC alone has faced roughly 750,000 IDR disputes, a number that fluctuates wildly from month to month.
Goldberg noted that HCSC has seen volume swings of up to 40% within a two-month period, making it nearly impossible to staff appropriately. To cope, the company currently employs over 400 individuals dedicated solely to processing IDR disputes. The cost of this specialized workforce, combined with the administrative fees associated with each arbitration case, is substantial. Watts’ data indicates that the IDR process has incurred approximately $5 billion in total costs from 2022 to 2024. These costs do not include the actual medical payments; they represent only the "overhead" of the dispute process itself.
Furthermore, Goldberg suggested that the volume may be intentionally manipulated by some entities to overwhelm insurers. By concentrating a massive number of claims in a short window, providers can make it difficult for insurers to respond within the strict statutory deadlines, potentially leading to default wins or rushed decisions by arbitrators.
The quality of the arbitration decisions is also under scrutiny. Goldberg shared a chilling anecdote regarding a $7,000 claim for a respiratory panel that resulted in a $255 million award due to an error by the IDR entity. While that specific error was eventually acknowledged and corrected after the insurer flagged it to CMS, Goldberg argued it is indicative of the "stress" arbitrators are under. With millions of cases to review, the quality of work is suffering, leading to errors that can have massive financial consequences.
Systemic Implications: The $80,000 Assistant Surgeon
The most significant concern for the panel was the inflationary pressure the current IDR system places on the healthcare economy. Katy Spangler provided a specific example of the price disconnect: an in-network lead surgeon may agree to a reimbursement of $800 for a procedure, yet an out-of-network assistant surgeon on the same case can take their claim to IDR and receive an $80,000 award.
This "unsustainable" disparity creates a perverse incentive structure. If out-of-network providers can consistently secure awards that are multiples of the in-network rate through arbitration, there is little reason for them to join an insurance network. This threatens to destabilize provider networks, as physicians may opt out of contracts to seek higher payouts via the IDR process. Ultimately, the $5 billion in administrative waste and the inflated award amounts are not absorbed by the insurance companies alone; they are passed on to employers and consumers in the form of higher monthly premiums.
The Path Forward: Regulatory and Legislative Solutions
As the healthcare industry looks toward the future of the No Surprises Act, the consensus among the AHIP panelists was that the status quo is untenable. Spangler argued that the current administration must take decisive regulatory action to protect the integrity of the law. Potential fixes include:
- Blocking Ineligible Claims: Establishing stricter gatekeeping mechanisms to ensure that claims entering the IDR portal meet all legal requirements, thereby reducing the "noise" and backlog.
- Addressing Incentives: Revising the guidance for arbitrators to ensure that awards are more closely aligned with market-based in-network rates (the QPA), rather than being influenced by inflated "charged" amounts.
- Batching Reform: Refining how claims are "batched" together for arbitration to prevent the system from being gamed by high-volume billing entities.
While regulatory changes can address some of the operational friction, there is a growing sense that congressional intervention may be necessary to close loopholes that allow for extreme award outcomes. The goal of such reforms would be to return the IDR process to its original intent: a "last resort" for legitimate payment disputes, rather than a primary revenue-generation strategy for out-of-network providers.
The No Surprises Act has undoubtedly achieved its primary goal of protecting patients from the "gotcha" of surprise medical bills. However, the data presented at the AHIP forum suggests that the "back-end" of the law is broken. Without swift intervention to streamline the IDR process and recalibrate the financial incentives, the very law intended to make healthcare more affordable may inadvertently contribute to the rising cost of coverage for all Americans. As Spangler concluded, "There’s a lot that we think can happen to make this less bad, but it’s really bad… we have got to fix this problem."
